ASCO: Gastric Cancer Patients Respond to Trastuzumab Deruxtecan
Overall survival also extended with conjugate treatment In a small, phase II trial, patients with advanced gastric cancer were far more likely to respond to conjugate therapy with trastuzumab deruxtecan (Enhertu) than with...